Letter: Dual Glucose-Ketone Monitoring as a Pump/AID Sick-Day Prevention Standard for Diabetic Ketoacidosis

Abstract

Get full access to this article

View all access options for this article.

References

Sherr

, Cobry

. The future of dual glucose-ketone monitoring in youth with diabetes. Diabetes Technol Ther, 2025; 27(S4):S36–S43.

Hoss

, Alva

, Pryor

, et al. Continuous dual glucose-ketone sensing technology. Diabetes Technol Ther, 2025; 27(S4):S20–S24.

Umpierrez

, Davis

, ElSayed

, et al. Hyperglycaemic crises in adults with diabetes: A consensus report. Diabetologia, 2024; 67(8):1455–1479.

Danne

, Garg

, Peters

, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with SGLT inhibitors. Diabetes Care, 2019; 42(6):1147–1154.

Ngan

, Kong

, Goad

, et al. Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: The PARTNER study. BMJ Open, 2025; 15(5):e098457; doi: 10.1136/bmjopen-2024-098457

Dhatariya

, Bergenstal

, Al-Sofiani

, et al. Continuous ketone monitoring for people with diabetes: International expert recommendations on the application of a new technology. Lancet Diabetes Endocrinol, 2026; 14(1):82–92; doi: 10.1016/S2213-8587(25)00331-6